Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Objectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are o...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sabine Schmid, MD, Lisa Holer, MSc, Katrin Gysel, MSc, Kira-Lee Koster, MD, Sacha I. Rothschild, MD, Laura A. Boos, MD, Lorenz Frehner, MD, Sabine Cardoso Almeida, MD, Christian Britschgi, MD, PhD, Yannis Metaxas, MD, Michael Mark, MD, Patrizia Froesch, MD, Wolf-Dieter Janthur, MD, Anna Allemann, MD, Christine Waibel, MD, Catherine Von der Mühll-Schill, MD, Martin Früh, MD, Laetitia A. Mauti, MD, PhD
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2024-12-01
Serie:	JTO Clinical and Research Reports
Soggetti:	Malignant pleural mesothelioma Ipilimumab Nivolumab Real-world Outcome
Accesso online:	http://www.sciencedirect.com/science/article/pii/S266636432400105X
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!